Introduction Of the estimated 10 million people worldwide who live with Parkinson’s disease (PD),1 over half will be expected to develop psychosis (hallucinations, illusions, delusions, or a false sense of presence).2,3 Pimavanserin (NUPLAZID®; ACADIA Pharmaceuticals Inc., San Diego, CA, USA) is an atypical antipsychotic developed for the treatment of hallucinations and delusions associated with PD […]
Trending Topic
Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages of the disease), troubling side effects associated with the available pharmacological treatments, a lack of effective disease-modifying therapies […]
Journal Archive
touchREVIEWS in Neurology is a peer-reviewed, free-to-access, bi-annual neurology journal comprising review articles, case reports, practice guides, theoretical discussions, and original research. It features balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the field of neurology.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
